245 related articles for article (PubMed ID: 27160069)
1. Searching for the Chokehold of NRAS Mutant Melanoma.
Posch C; Vujic I; Monshi B; Sanlorenzo M; Weihsengruber F; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Jul; 136(7):1330-1336. PubMed ID: 27160069
[TBL] [Abstract][Full Text] [Related]
2. Nras in melanoma: targeting the undruggable target.
Mandalà M; Merelli B; Massi D
Crit Rev Oncol Hematol; 2014 Nov; 92(2):107-22. PubMed ID: 24985059
[TBL] [Abstract][Full Text] [Related]
3. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
Fedorenko IV; Gibney GT; Smalley KS
Oncogene; 2013 Jun; 32(25):3009-18. PubMed ID: 23069660
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.
Duggan MC; Regan-Fendt K; Olaverria Salavaggione GN; Howard JH; Stiff AR; Sabella J; Latchana N; Markowitz J; Gru A; Tridandapani S; Eisfeld AK; de la Chapelle A; Carson WE
Melanoma Res; 2019 Oct; 29(5):491-500. PubMed ID: 31116161
[TBL] [Abstract][Full Text] [Related]
6. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
7. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.
Johnson DB; Smalley KS; Sosman JA
Clin Cancer Res; 2014 Aug; 20(16):4186-92. PubMed ID: 24895460
[TBL] [Abstract][Full Text] [Related]
9. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
11. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
13. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutant NRAS signaling pathways in melanoma.
Vu HL; Aplin AE
Pharmacol Res; 2016 May; 107():111-116. PubMed ID: 26987942
[TBL] [Abstract][Full Text] [Related]
15. Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
Chagani S; Wang R; Carpenter EL; Löhr CV; Ganguli-Indra G; Indra AK
BMC Cancer; 2017 Nov; 17(1):736. PubMed ID: 29121869
[TBL] [Abstract][Full Text] [Related]
16. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
17. Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.
McConnell AM; Mito JK; Ablain J; Dang M; Formichella L; Fisher DE; Zon LI
Dev Biol; 2019 May; 449(2):107-114. PubMed ID: 29883661
[TBL] [Abstract][Full Text] [Related]
18.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]